Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude du BGB-16673 par rapport au choix de l'investigateur chez les participants atteints de leucémie lymphocytaire chronique auparavant exposée à la fois à la Bruton Tyrosine kinase (BTK) et aux inhibiteurs de la leucémie / lymphome 2 à cellules B (BCL2) (CaDAnCe-302)

25 septembre 2026 mis à jour par: BeOne Medicines

Une phase 3, une étude randomisée en phase 3 du BGB-16673 par rapport au choix de l'investigateur (Idelalisib plus rituximab ou bendamustine plus rituximab ou vénémié plus vénémière plus au rituximab) chez les patients atteints d'inhibiteurs chroniques lymphocytiques

The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Aperçu de l'étude

Description détaillée

Chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, weight loss and fever. They have shorter life expectancy compared to healthy people. There is an urgent need for new treatment to prolong life and control disease-related symptoms.

In this study, participants with relapsed/refractory (R/R) CLL who were previously exposed to a BTKi and a BCL2i will receive tacabrutideg or the investigator's choice of idelalisib plus rituximab (for CLL only) or bendamustine plus rituximab or venetoclax plus rituximab retreatment. The main purpose of this study is to compare the length of time that participants live without their CLL or SLL worsening between those participants who receive tacabrutideg versus the investigator's choice of treatment (idelalisib plus rituximab or bendamustine plus rituximab, or venetoclax plus rituximab).

Approximately 250 participants will be included in this study around the world. Participants will be randomly allocated to receive either tacabrutideg or the investigator's choice of treatment.

"Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website."

Type d'étude

Interventionnel

Inscription (Estimé)

250

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Augsburg, Allemagne, 86156
        • Recrutement
        • Universitatsklinikum Augsburg
      • Berlin, Allemagne, 10715
        • Recrutement
        • Praxis Am Volkspark
      • Chemnitz, Allemagne, 09116
        • Recrutement
        • Klinikum Chemnitz Ggmbh
      • Essen, Allemagne, 45122
        • Recrutement
        • Universitatsklinikum Essen (Aor)
      • Frankfurt am Main, Allemagne, 60389
        • Recrutement
        • Centrum Fur Haematologie Und Onkologie Bethanien
      • Freiburg im Breisgau, Allemagne, 79106
        • Recrutement
        • Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
      • Hamburg, Allemagne, 20251
        • Recrutement
        • Universitatsklinikum Hamburg Eppendorf
      • Heidelberg, Allemagne, 69120
        • Recrutement
        • Universitatsklinikum Heidelberg
      • Homburg, Allemagne, 66421
        • Recrutement
        • Universitatsklinikum Des Saarlandes
      • Koblenz, Allemagne, 56068
        • Recrutement
        • Invo Institut Fur Versorgungsforschung in Der Onkologie
      • Leipzig, Allemagne, 04103
        • Recrutement
        • Universitaetsklinikum Leipzig Aor
      • Münster, Allemagne, 48149
        • Recrutement
        • Universitatsklinikum Munster Medizinische Klinik A
      • Caba, Argentine, CP1114
        • Recrutement
        • FUNDALEU
      • Caba, Argentine, C1431
        • Recrutement
        • CEMIC
      • Caba, Argentine, 1425
        • Recrutement
        • Hospital Aleman
      • Ciudad Autonoma Buenos Aires, Argentine, 1413
        • Recrutement
        • Hospital Italiano de Buenos Aires
      • Ciudad Autonoma Buenos Aires, Argentine, 1426
        • Recrutement
        • Instituto Alexander Fleming (Iaf)
      • San Miguel de Tucumán, Argentine, 4000
        • Recrutement
        • Cice 9 de Julio Sanatorio 9 de Julio
    • New South Wales
      • Concord, New South Wales, Australie, NSW 2139
        • Recrutement
        • Concord Repatriation General Hospital
      • Gosford, New South Wales, Australie, NSW 2250
        • Recrutement
        • Gosford Hospital
      • Port Macquarie, New South Wales, Australie, NSW 2444
        • Recrutement
        • Port Macquarie Base Hospital
      • Randwick, New South Wales, Australie, NSW 2031
        • Recrutement
        • Prince of Wales Hospital
    • Queensland
      • Toowoomba, Queensland, Australie, QLD 4350
        • Recrutement
        • Toowoomba Hospital
    • South Australia
      • Bedford PK, South Australia, Australie, SA 5042
        • Recrutement
        • Flinders Medical Centre
    • Victoria
      • Melbourne, Victoria, Australie, VIC 3004
        • Recrutement
        • The Alfred Hospital
    • Western Australia
      • West Perth, Western Australia, Australie, WA 6005
        • Recrutement
        • Perth Blood Institute
      • Belo Horizonte, Brésil, 30110-022
        • Recrutement
        • CETUS
      • Brasília, Brésil, 70200-730
        • Recrutement
        • Hospital Sirio Libanes Brasilia
      • Curitiba, Brésil, 81520-060
        • Recrutement
        • Hospital Erasto Gaertner
      • Florianópolis, Brésil, 88020-210
        • Recrutement
        • Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
      • Joinville, Brésil, 89201-260
        • Recrutement
        • Instituto Joinvilense de Hematologia E Oncologia
      • Niterói, Brésil, 24020-096
        • Recrutement
        • Complexo Hospitalar de Niteroi
      • Porto Alegre, Brésil, 90110-270
        • Recrutement
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Rio de Janeiro, Brésil, 22250-040
        • Recrutement
        • Oncoclinicas Rio de Janeiro Sa
      • Rio de Janeiro, Brésil, 22061-080
        • Recrutement
        • Hospital Sao Lucas Dasa Oncologia
      • Salvador, Brésil, 41253-190
        • Recrutement
        • Hospital Sao Rafael (Rede Dor)
      • São Paulo, Brésil, 05652-900
        • Recrutement
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brésil, 04014-002
        • Recrutement
        • Instituto Brasileiro de Controle Do Cancer
      • São Paulo, Brésil, 01401-004
        • Recrutement
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
      • Vitória, Brésil, 29043-260
        • Recrutement
        • Hospital Santa Rita de Cassia Afecc
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Recrutement
        • Juravinski Cancer Centre
      • London, Ontario, Canada, N6A 5W9
        • Recrutement
        • London Health Sciences Centre
      • Ottawa, Ontario, Canada, K1H 8L6
        • Recrutement
        • The Ottawa Hospital Cancer Centre
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Recrutement
        • Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
      • Montreal, Quebec, Canada, QC H3t 1E2
        • Recrutement
        • Jewish General Hospital
      • SaintJerome, Quebec, Canada, J7Z 5T3
        • Recrutement
        • Unite de Recherche Clinique Du Cisss Des Laurentides
    • Busan Gwang'yeogsi
      • Seogu, Busan Gwang'yeogsi, Corée du Sud, 49201
        • Recrutement
        • Dong A University Hospital
    • Daegu Gwang'yeogsi
      • Junggu, Daegu Gwang'yeogsi, Corée du Sud, 41944
        • Recrutement
        • Kyungpook National University Hospital
    • Gyeonggi-do
      • IlsandongGu GoyangSi, Gyeonggi-do, Corée du Sud, 10408
        • Recrutement
        • National Cancer Center (Korea)
    • Jeonnam-Gwangju S.M. City
      • HwasunGun, Jeonnam-Gwangju S.M. City, Corée du Sud, 58128
        • Recrutement
        • Chonnam National University Hwasun Hospital
    • Seoul Teugbyeolsi
      • GangnamGu, Seoul Teugbyeolsi, Corée du Sud, 06351
        • Recrutement
        • Samsung Medical Center
      • SeochoGu, Seoul Teugbyeolsi, Corée du Sud, 06591
        • Recrutement
        • The Catholic University of Korea, Seoul St Marys Hospital
      • Seoul, Seoul Teugbyeolsi, Corée du Sud, 03080
        • Recrutement
        • Seoul National University Hospital
      • Bari, Italie, 70124
        • Recrutement
        • Irccs Istituto Tumori Giovanni Paolo Ii
      • Florence, Italie, 50134
        • Recrutement
        • Aou Careggi, Servizio Sanitario Toscana
      • Milan, Italie, 20132
        • Recrutement
        • Ospedale San Raffaele
      • Milan, Italie, 20122
        • Recrutement
        • Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
      • Naples, Italie, 80131
        • Recrutement
        • Azienda Ospedaliera Universitaria Federico Ii
      • Novara, Italie, 28100
        • Recrutement
        • Aou Maggiore Della Carita
      • Pavia, Italie, 27100
        • Recrutement
        • Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
      • Perugia, Italie, 6129
        • Recrutement
        • Ospedale Santa Maria Della Misericordia
      • Roma, Italie, 00168
        • Recrutement
        • Fondazione Policlinico Universitario Agostino Gemelli
      • Kumamoto, Japon, 860-8556
        • Recrutement
        • Kumamoto University Hospital
      • Okayama, Japon, 701-1192
        • Recrutement
        • National Hospital Organization Okayama Medical Center
      • Osaka, Japon, 545-8586
        • Recrutement
        • Osaka Metropolitan University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 464-8681
        • Recrutement
        • Aichi Cancer Center Hospital Clinical Oncology
    • Chiba
      • Chiba, Chiba, Japon, 260-8717
        • Recrutement
        • Chiba Cancer Center
    • Ehime
      • Matsuyama, Ehime, Japon, 791-0280
        • Recrutement
        • Nho Shikoku Cancer Center
    • Hiroshima
      • Hiroshima, Hiroshima, Japon, 730-8619
        • Recrutement
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japon, 064-0804
        • Recrutement
        • Aiiku Hospital
    • Hyōgo
      • AmagasakiCity, Hyōgo, Japon, 660-8550
        • Recrutement
        • Hyogo Prefectural Amagasaki General Medical Center
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japon, 890-8520
        • Recrutement
        • Kagoshima University Hospital
    • Kyoto
      • KyotoShi, Kyoto, Japon, 602-8566
        • Recrutement
        • University Hospital, Kyoto Prefectural Univ of Medicine
    • Miyagi
      • Sendai, Miyagi, Japon, 980-8574
        • Recrutement
        • Tohoku University Hospital
    • Niigata
      • Niigata, Niigata, Japon, 951-8520
        • Recrutement
        • Niigata University Medical and Dental Hospital
    • Okayama-ken
      • Kurashikishi, Okayama-ken, Japon, 710-8602
        • Recrutement
        • Kurashiki Central Hospital
    • Osaka
      • Hirakata, Osaka, Japon, 573-1191
        • Recrutement
        • Kansai Medical University Hospital
      • Sakai, Osaka, Japon, 590-0197
        • Recrutement
        • Kindai University Hospital
    • Saitama
      • Kawagoeshi, Saitama, Japon, 350-8550
        • Recrutement
        • Saitama Medical Center
    • Tokyo
      • Bunkyoku, Tokyo, Japon, 113-8677
        • Recrutement
        • Tokyo Metropolitan Komagome Hospital
      • Shinagawaku, Tokyo, Japon, 141-0022
        • Recrutement
        • Ntt Medical Center Tokyo
      • Amsterdam, Pays-Bas, 1081 HV
        • Recrutement
        • Amsterdam Umc Vu Mc
      • Brzozów, Pologne, 36-200
        • Recrutement
        • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
      • Katowice, Pologne, 40-519
        • Recrutement
        • Pratia Onkologia Katowice
      • Krakow, Pologne, 30-727
        • Recrutement
        • Pratia McM Krakow
      • Lodz, Pologne, 93-513
        • Recrutement
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin, Pologne, 20-090
        • Recrutement
        • Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
      • Wroclaw, Pologne, 50-367
        • Recrutement
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
      • Aberdeen, Royaume-Uni, AB25 2ZN
        • Recrutement
        • Aberdeen Royal Infirmary
      • Birmingham, Royaume-Uni, B9 5SS
        • Recrutement
        • Birmingham Heartlands Hospital
      • Bournemouth, Royaume-Uni, BH7 7DW
        • Recrutement
        • The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
      • London, Royaume-Uni, SW3 6JJ
        • Recrutement
        • Royal Marsden Hospital
      • London, Royaume-Uni, NW1 2PG
        • Recrutement
        • University College Hospital
      • Southampton, Royaume-Uni, SO16 6YD
        • Recrutement
        • Southampton General Hospital
      • Brno, Tchéquie, 625 00
        • Recrutement
        • Fakultni Nemocnice Brno
      • Hradec Králové, Tchéquie, 500 03
        • Recrutement
        • Fakultni Nemocnice Hradec Kralove
      • Ostrava, Tchéquie, 708 00
        • Recrutement
        • Fakultni Nemocnice Ostrava
      • Prague, Tchéquie, 10000
        • Recrutement
        • Vseobecna Fakultni Nemocnice V Praze
      • Ankara, Turquie (Türkiye), 6500
        • Recrutement
        • Gazi University
      • Ankara, Turquie (Türkiye), 06200
        • Recrutement
        • Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
      • Balçova, Turquie (Türkiye), 35330
        • Recrutement
        • Dokuz Eylul University
      • Dokuma, Turquie (Türkiye), 07025
        • Recrutement
        • Antalya Memorial Hospital
      • Sakarya, Turquie (Türkiye), 54100
        • Recrutement
        • Sakarya Training and Research Hospital
    • Arkansas
      • Jonesboro, Arkansas, États-Unis, 72401
        • Recrutement
        • St Bernards Medical Center
    • California
      • Los Angeles, California, États-Unis, 90095-3075
        • Recrutement
        • UCLA Department of Medicine Hematologyoncology
      • San Diego, California, États-Unis, 92103-2106
        • Recrutement
        • Scripps Prebys Cancer Center
      • Whittier, California, États-Unis, 90602
        • Recrutement
        • Pih Health Whittier Hospital
    • Colorado
      • Aurora, Colorado, États-Unis, 80012-5405
        • Recrutement
        • Rocky Mountain Cancer Centers (Williams) Usor
      • Golden, Colorado, États-Unis, 80401
        • Recrutement
        • Intermountain Health Lutheran Hospital Cancer Center of Colorado
    • Florida
      • Fort Myers, Florida, États-Unis, 33912
        • Recrutement
        • Florida Oncology and Hematology
      • Jacksonville, Florida, États-Unis, 32207-8432
        • Recrutement
        • Baptist Md Anderson Cancer Center
      • Weston, Florida, États-Unis, 33331-3609
        • Recrutement
        • Cleveland Clinic Florida
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322-1013
        • Recrutement
        • Emory University Winship Cancer Institute
      • Atlanta, Georgia, États-Unis, 30342
        • Recrutement
        • Northside Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, États-Unis, 70808-4365
        • Recrutement
        • Our Lady of the Lake Hospital
    • Maryland
      • Bethesda, Maryland, États-Unis, 20817-7847
        • Recrutement
        • American Oncology Partners of Maryland Pa
    • Michigan
      • Grand Rapids, Michigan, États-Unis, 49503-2560
        • Recrutement
        • Corewell Health the Michigan Cancer Consortium
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55455-0341
        • Recrutement
        • University of Minnesota
    • Missouri
      • Chesterfield, Missouri, États-Unis, 63017
        • Recrutement
        • St Lukes Center For Cancer Care
      • Springfield, Missouri, États-Unis, 65807-5288
        • Recrutement
        • Oncology Hematology Associates
    • Montana
      • Billings, Montana, États-Unis, 59102-6746
        • Recrutement
        • St Vincent Frontier Cancer Center
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68130-2042
        • Recrutement
        • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
    • New York
      • New York, New York, États-Unis, 10065-6800
        • Recrutement
        • Memorial Sloan Kettering Cancer Center Mskcc
      • Shirley, New York, États-Unis, 11967
        • Recrutement
        • New York Cancer and Blood Specialists
      • Westbury, New York, États-Unis, 11590-5119
        • Recrutement
        • Optum Medical Care, Pc
    • Ohio
      • Cleveland, Ohio, États-Unis, 44106-1716
        • Recrutement
        • University Hospitals
      • Dayton, Ohio, États-Unis, 45415
        • Recrutement
        • Dayton Physician Network
    • Oregon
      • Eugene, Oregon, États-Unis, 97401
        • Recrutement
        • Oncology Associates of Oregon Willamette Valley Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15224
        • Recrutement
        • West Penn Hospital
      • York, Pennsylvania, États-Unis, 17403-5049
        • Recrutement
        • Cancer Care Associates of York
    • Texas
      • Temple, Texas, États-Unis, 76508-0001
        • Recrutement
        • Baylor Scott and White Health
      • Tyler, Texas, États-Unis, 75702-7522
        • Recrutement
        • Texas Oncology Tyler

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
  2. Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
  3. Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI)
  4. Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
  5. Adequate liver function
  6. Adequate blood clotting function

Exclusion Criteria:

  1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
  2. Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 3 months
  3. Known central nervous system involvement
  4. Prior exposure to any BTK protein degraders
  5. Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy
  6. Clinically significant cardiovascular disease

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm A: Tacabrutideg monotherapy

Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met

Administered orally

Autres noms:
  • BGB-16673
Comparateur actif: Arm B: Investigator's Choice

Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment.

Administered orally

Administered intravenously

Administered intravenously

Administered orally

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Délai: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

Approximately 36 Months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall Survival (OS)
Délai: Approximately 36 Months

OS is defined as time from the date of randomization to the date of death due to any cause.

Approximately 36 Months
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
Délai: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL for participants with prior exposure to ncBTKi.

Approximately 36 Months
PFS by the Investigator Assessment
Délai: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL

Approximately 36 Months
Overall Response Rate (ORR) by IRC and Investigator Assessment
Délai: Approximately 36 Months

ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (Cri), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator.

Approximately 36 Months
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
Délai: Approximately 36 Months

Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator

Approximately 36 Months
Duration of Response (DOR) by IRC and Investigator Assessment
Délai: Approximately 36 Months

DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator.

Approximately 36 Months
Time to Next Anti-CLL/SLL Treatment (TTNT)
Délai: Approximately 36 Months

TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment.

Approximately 36 Months
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Délai: Approximately 36 Months

Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

Approximately 36 Months
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire -Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) and Physical Functioning Scales
Délai: Approximately 24 Months

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). Higher scores in GHS and functional scales indicate better quality of life.

Approximately 24 Months
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
Délai: Approximately 24 Months

The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning.

Approximately 24 Months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Study Director, BeOne Medicines

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 avril 2025

Achèvement primaire (Estimé)

15 mai 2028

Achèvement de l'étude (Estimé)

14 février 2030

Dates d'inscription aux études

Première soumission

21 février 2025

Première soumission répondant aux critères de contrôle qualité

21 février 2025

Première publication (Réel)

26 février 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

25 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Délai de partage IPD

See plan description

Critères d'accès au partage IPD

See plan description

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner